ABSTRACT
New 2-aryliminopyrrolidines (1-18) were synthesized and tested for their binding properties on I1 imidazoline receptors vs α2-adrenergic receptors and their blood pressure effects after both systemic and intracerebral administrations. The purposes of this study were: (i) to analyze structure-activity and affinity relationships on I1 imdazoline receptors and (ii) to propose some leader compounds for the development of new sympatho-inhibitory drugs with potential applications in hypertension and/or metabolic syndrome, i.e., a cluster of cardiovascular (hypertension) and metabolic disorders. Our study highlights decisive arguments of SAR concerning both the affinity for I1Rs and the hypotensive activity of 2-aryliminopyrrolidines. Binding assays showed high affinity and selectivity of some compounds for I1 imidazoline receptors over α2-adreergic receptors. Compound 13 (laboratory reference LNP599; Ki = 3.2 nM on I1imidazoline receptors) is the prototype for the development of new centrally acting agents targeting specifically I1imidazoline receptors to be used in the management of hypertension and/or metabolic syndrome.
Subject(s)
Antihypertensive Agents/chemical synthesis , Imidazoline Receptors/metabolism , Metabolic Syndrome/drug therapy , Pyrrolidines/chemical synthesis , Sympatholytics/chemical synthesis , Animals , Antihypertensive Agents/pharmacology , Blood Pressure/drug effects , Blood-Brain Barrier , Drug Discovery , Heart Rate/drug effects , Ligands , Pyrrolidines/pharmacology , Rats , Rats, Wistar , Structure-Activity Relationship , Sympatholytics/pharmacologyABSTRACT
Based on the known biological activity of a variety of guanidine-containing agents, several N-substituted 3,4-dihydroquinazolines were synthesized. These compounds can be considered to be rigid analogues of phenylguanidines. In anesthetized rats the compounds decreased blood pressure and were antagonists of the pressor response to norepinephrine.
Subject(s)
Quinazolines/chemical synthesis , Sympatholytics/chemical synthesis , Animals , Blood Pressure/drug effects , Chemical Phenomena , Chemistry , Male , Norepinephrine/pharmacology , Quinazolines/pharmacology , RatsABSTRACT
Since the introduction of radioiodinated m-iodobenzylguanidine in 1980, much research has been performed, both in the chemical field as well as in medical sciences. This paper reviews the synthesis, radiolabelling and stability of radioiodinated m-iodobenzylguanidine. Regarding the many radiolabelling procedures for m-iodobenzylguanidine, the Cu(1+)-assisted nucleophilic exchange radioiodination can be considered as the method of first choice. Quality control of the radiopharmaceutical product is discussed and attention is paid to recent studies regarding the radiochemical stability of iodine-131 labelled m-iodobenzylguanidine.